Pfizer Inc.

ticker: PFE step: 01 generated: 2026-05-12 source: quick-research

Pfizer Inc. (PFE) — Business Overview

Business Description

Pfizer is one of the world's largest research-based biopharmaceutical companies, operating in 125+ countries with significant sales in North America, Europe, and emerging markets. The company is in the middle of a multi-year strategic pivot — diversifying away from COVID-era windfalls and toward a portfolio anchored by oncology (post-Seagen), vaccines, rare diseases, and a newly aggressive obesity push (Metsera acquisition). Six priority therapeutic areas: Oncology, Vaccines, Inflammation & Immunology, Rare Diseases, Internal Medicine, and Anti-Infectives.

Revenue Model

• Branded pharmaceutical sales (~98% of revenue): Direct sales to pharmacies, hospitals, payers, and PBMs in the US plus international markets (mostly via subsidiaries). Pricing is list-minus-rebate in the US, with materially lower realized prices ex-US.
• Vaccines: Prevnar 20 (pneumococcal), COVID products (Comirnaty + Paxlovid — declining), Abrysvo (RSV), routine immunization franchises (e.g., Trumenba).
• Oncology (28% of revenue, growing fast): Ibrance, Xtandi (partnered with Astellas), Lorbrena, Braftovi/Mektovi, plus the four marketed Seagen ADCs — ADCETRIS, PADCEV, TIVDAK, TUKYSA. Combined oncology contributed $3.4B from Seagen products in FY2024.
• Internal Medicine: Eliquis (with BMS), Vyndaqel family (transthyretin amyloidosis), Pristiq, Lyrica generics.
• Specialty / Inflammation & Immunology: Xeljanz, Cibinqo, Litfulo.
• Royalties & collaborations: Income from partnerships including BMS on Eliquis, Astellas on Xtandi.

The strategic narrative is shifting from blockbuster small-molecule primary care toward higher-margin, longer-duration oncology biologics and ADCs.

Products & Services

Vaccines:

• Comirnaty (COVID-19 mRNA, with BioNTech)
• Prevnar 20 (pneumococcal)
• Abrysvo (RSV for older adults and maternal)
• Trumenba (meningitis B)

Oncology:

• Ibrance (palbociclib) — CDK4/6 inhibitor
• Xtandi (enzalutamide) — prostate cancer
• Vyndaqel / Vyndamax (tafamidis) — ATTR-CM
• Lorbrena (lorlatinib) — NSCLC
• ADCETRIS, PADCEV, TIVDAK, TUKYSA (Seagen ADCs)
• Talzenna, Braftovi/Mektovi, Bavencio (with Merck KGaA)

Internal Medicine / Cardiometabolic:

• Eliquis (apixaban, with BMS)
• Vyndaqel family
• Metsera obesity portfolio (post $10B acquisition)

Inflammation & Immunology:

• Xeljanz, Cibinqo, Litfulo, Inflectra

Rare Disease / Hematology:

• BENEFIX, REFACTO AF, Beqvez (gene therapy)

Anti-Infectives:

• Paxlovid (COVID antiviral, declining)
• Zithromax, antibacterials

Pipeline (April 2025): 108 total candidates — 47 Phase 1, 28 Phase 2, 30 Phase 3, 3 pending approval.

Customer Base & Go-to-Market

• US (~50% of revenue): Sold through PBMs, retail pharmacies, hospitals, specialty distributors; significant DTC marketing for Eliquis, Vyndaqel family, Abrysvo.
• International (~50%): Direct sales subsidiaries in 100+ countries; Europe, Japan, China are largest markets. Emerging markets growing as middle-class healthcare access expands.
• Hospital & specialty channels: Heavily weighted for oncology and rare disease franchises.
• Government / public health: Vaccines (Prevnar, RSV, COVID) — payer mix includes Medicare Part B/D, CDC, GAVI, Ministry-level contracts globally.

No single customer represents material concentration. Geographic diversification is one of Pfizer's structural strengths.

Competitive Position

Pfizer is one of the top 5 global pharmaceutical companies by revenue (~$63B FY2024) and a top-tier presence in vaccines, oncology, and cardiometabolic. Key strengths: (1) Seagen ADC platform — the $43B Seagen acquisition (Dec 2023) gave Pfizer industry-leading ADC technology in target-selection, linkers, payloads, and manufacturing; oncology pipeline targeting $10B+ revenue by 2030, (2) Vyndaqel franchise — sole leader in ATTR amyloidosis indication with multi-year growth runway, (3) Vaccine R&D + manufacturing — Comirnaty mRNA platform plus traditional vaccine production capacity, (4) Metsera obesity entry — acquired for $10B after a public bidding war with Novo Nordisk, providing pipeline entry into GLP-1 / cardiometabolic alongside Lilly and Novo, (5) Cost reset — $7.7B cost reduction program by 2027 (with $500M reinvested into R&D productivity). Key weaknesses: $15–18B annual revenue loss from 2026–2028 patent cliffs (Eliquis, Ibrance, Xtandi, Prevnar 13), stretched balance sheet from Seagen + Metsera M&A, and underperformance vs. Lilly / Novo in obesity through 2025.

Key Facts

• Founded: 1849
• Headquarters: New York, NY
• Employees: ~88,000
• Exchange: NYSE
• Sector / Industry: Health Care / Pharmaceuticals
• Market Cap: ~$146B (May 2026)
• Dividend yield: ~6% — one of the highest in big pharma

ticker: PFE step: 04 generated: 2026-05-12 source: quick-research

Pfizer Inc. (PFE) — Financial Snapshot

Income Statement Summary

Top Products (FY2024)

2026 Guidance

Patent Cliff Detail

Cash Flow & Balance Sheet (FY2025)

Key Ratios (approximate, May 2026)

• P/E (forward): ~10x | EV/EBITDA: ~9x | Dividend Yield: ~6.3%
• ROIC: ~9% (pre-Metsera)
• FCF Yield: ~7%

Growth Profile

FY25 revenue $62.6B (-2%) — COVID franchise headwind continues. Ex-COVID operational +6%. Eliquis +9% in 2024 but facing IRA Medicare negotiated price in 2026 = -$1B headwind. Seagen integration progressing. Patent cliff: $21.4B of 2024 revenue at risk through 2028. Obesity gap until MET097 in 2028. Pfizer reaffirmed 2026 guidance of $59.5-62.5B.

Forward Estimates

• FY2026E Revenue: $59.5-62.5B (mgmt guide; flat to -3%)
• FY2026E Adj EPS: ~$3.20-3.30
• FY2027E EPS: ~$3.00 (LOE peak headwind)
• FY2028E EPS: ~$3.50+ (MET097 launch potential)
• 2030+ Obesity Revenue (bull case): $5-10B+

Capital Return

• Dividend $1.72 annual (~$9.7B paid) — 6.3% yield
• 15+ consecutive years of dividend growth
• Buybacks suspended for Seagen deleveraging
• Dividend coverage tight but management committed

ticker: PFE step: 12 generated: 2026-05-12 source: quick-research

Pfizer Inc. (PFE) — Investment Catalysts & Risks

Bull Case Drivers

1. Seagen ADC integration + Padcev first-line bladder — $43B Seagen acquisition integrated. Padcev + Keytruda combination is now first-line standard of care in bladder cancer. Multiple ADC pipeline candidates emerging from Seagen platform. Pfizer dedicating >40% R&D spend to oncology. ADCs represent the highest-growth oncology modality (alongside cell therapy).

2. Obesity entry via Metsera + 10 Phase III MET097 trials — $10B Metsera acquisition + YP05002 in-licensing. 10 Phase III trials starting on MET097 (ultra-long-acting GLP-1). Launch target 2028. Global obesity market ~$150B by 2030. While Pfizer is 3+ years behind Lilly/Novo, capturing even 10% of the obesity market = $15B annual revenue.

3. 6.3% dividend yield + cost discipline — Highest dividend yield among large-cap pharma at 6.3%. Adj operating margin expanded 21% (FY23) → 27% (FY25) through cost reductions. Combined with 15+ consecutive years of dividend growth, PFE offers high-yield defensive profile if the patent cliff is navigated.

4. Bourla leadership refresh signals R&D rebuild — In 2025 Bourla elevated Chris Boshoff to CSO + brought in Jeff Legos from Novartis as CRO to fix R&D engine + Seagen integration. Aggressive cost program targeting $4B+ annual savings to fund pipeline.

Bear Case Risks

1. Patent cliff is largest in industry — $21.4B at risk through 2028 — Pfizer's products with patent losses 2026-2027 generated $21.4B in 2024 (~1/3 of revenue). LOE headwind growing from $1.5B (2025) → $4.5B (2027). Ibrance LOE 2027, Eliquis IRA pressure 2026, Vyndaqel LOE 2028. No obesity launch until 2028.

2. Eliquis IRA Medicare price negotiation — $1B 2026 hit — Eliquis is #1 product subject to Medicare price negotiation. New price effective Jan 2026 cuts $1B from revenue (-1.6% growth headwind). This is a structural reset — future Eliquis revenue will be permanently lower than pre-IRA trajectory.

3. Obesity gap until 2028 = 2-year vulnerability — MET097 not launching before 2028 = 2-year window of Lilly Mounjaro/Zepbound + Novo Wegovy expanding market share. By 2028, oral GLP-1s (Lilly orforglipron) will be commercial. Pfizer entering obesity late + with a 2nd-generation product = uphill battle. Danuglipron failure (discontinued 2025) erased early momentum.

4. TrumpRx pricing + acquisition track record — "TrumpRx" environment in 2026 limits ability to take annual price hikes. Bourla's M&A track record questioned — bears note prior large deals (Warner-Lambert, Wyeth, Allergan, Hospira) had mixed returns. Investors skeptical that "buy our way out of patent cliff" works.

Upcoming Events

• Q2 2026 earnings (July 2026) — Eliquis post-IRA negotiated price trajectory; LOE drug performance
• Q3 2026 earnings (October 2026) — Mid-year reconfirmation of guidance
• MET097 first Phase III readouts — Late 2026 / 2027 — critical for obesity timeline
• Comirnaty fall 2026 vaccination season — Continued normalization
• Padcev label expansion data

Analyst Sentiment

Sell-side consensus is Hold / Moderate Buy with average price targets in the $30-32 range vs. recent ~$27 trading levels (~11-19% upside). Bulls cite 6.3% dividend yield, Seagen oncology integration, and Metsera optionality. Bears focus on patent cliff, Eliquis IRA reset, and 3-year obesity gap. Pfizer is a value name with binary obesity catalyst — most analysts see "wait and see" until MET097 Phase III data.

Research Date

Generated: 2026-05-12